326 related articles for article (PubMed ID: 6895481)
1. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans.
Riccardi R; Holcenberg JS; Glaubiger DL; Wood JH; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4554-8. PubMed ID: 6895481
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of PEG-L-asparaginase and plasma and cerebrospinal fluid L-asparagine concentrations in the rhesus monkey.
Berg SL; Balis FM; McCully CL; Godwin KS; Poplack DG
Cancer Chemother Pharmacol; 1993; 32(4):310-4. PubMed ID: 8324873
[TBL] [Abstract][Full Text] [Related]
4. Levels of L-asparagine in CSF after intramuscular administration of asparaginase from Erwinia in children with acute lymphoblastic leukemia.
Dibenedetto SP; Di Cataldo A; Ragusa R; Meli C; Lo Nigro L
J Clin Oncol; 1995 Feb; 13(2):339-44. PubMed ID: 7844595
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia.
Woo MH; Hak LJ; Storm MC; Gajjar AJ; Sandlund JT; Harrison PL; Wang B; Pui CH; Relling MV
J Clin Oncol; 1999 May; 17(5):1568-73. PubMed ID: 10334545
[TBL] [Abstract][Full Text] [Related]
6. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
[TBL] [Abstract][Full Text] [Related]
7. L-Asparagine depletion levels and L-asparaginase activity in plasma of children with acute lymphoblastic leukemia under asparaginase treatment.
Tsurusawa M; Chin M; Iwai A; Nomura K; Maeba H; Taga T; Higa T; Kuno T; Hori T; Muto A; Yamagata M;
Cancer Chemother Pharmacol; 2004 Mar; 53(3):204-8. PubMed ID: 14634792
[TBL] [Abstract][Full Text] [Related]
8. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia.
Rizzari C; Citterio M; Zucchetti M; Conter V; Chiesa R; Colombini A; Malguzzi S; Silvestri D; D'Incalci M
Haematologica; 2006 Jan; 91(1):24-31. PubMed ID: 16434367
[TBL] [Abstract][Full Text] [Related]
9. Antibody formation during intravenous and intramuscular therapy with Erwinia asparaginase.
Albertsen BK; Schrøder H; Jakobsen P; Avramis VI; Müller HJ; Schmiegelow K; Carlsen NT
Med Pediatr Oncol; 2002 May; 38(5):310-6. PubMed ID: 11979454
[TBL] [Abstract][Full Text] [Related]
10. L-asparagine depletion and L-asparaginase activity in children with acute lymphoblastic leukemia receiving i.m. or i.v. Erwinia C. or E. coli L-asparaginase as first exposure.
Rizzari C; Zucchetti M; Conter V; Diomede L; Bruno A; Gavazzi L; Paganini M; Sparano P; Lo Nigro L; Aricò M; Milani M; D'Incalci M
Ann Oncol; 2000 Feb; 11(2):189-93. PubMed ID: 10761754
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of Erwinia asparaginase therapy in childhood ALL in the Nordic countries.
Albertsen BK; Schrøder H; Jakobsen P; Müller HJ; Carlsen NT; Schmiegelow K
Br J Clin Pharmacol; 2001 Oct; 52(4):433-7. PubMed ID: 11678787
[TBL] [Abstract][Full Text] [Related]
12. Gel entrapped L-asparaginase: kinetic behavior and antitumor activity.
O'Driscoll KF; Korus RA; Ohnuma T; Walczack IM
J Pharmacol Exp Ther; 1975 Nov; 195(2):382-8. PubMed ID: 241845
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid pharmacokinetics of intraventricular and intravenous aziridinylbenzoquinone.
Zimm S; Collins JM; Curt GA; O'Neill D; Poplack DG
Cancer Res; 1984 Apr; 44(4):1698-701. PubMed ID: 6704975
[TBL] [Abstract][Full Text] [Related]
14. [Research on the pharmacokinetics and pharmacodynamics of L-asparaginase during its treatment of childhood acute lymphoblastic leukemia].
Chen FX; Cui YQ; Wu ZL; Ye TZ; Lai YH; Zou YW; Lu CY; Guan JM; Wei FG; Zhang H
Zhonghua Xue Ye Xue Za Zhi; 2005 Feb; 26(2):100-2. PubMed ID: 15921627
[TBL] [Abstract][Full Text] [Related]
15. Entrapment of L-asparaginase in red blood cells. A strategy to improve treatment of acute lymphoblastic leukemia.
Updike SJ
Bibl Haematol; 1985; (51):65-74. PubMed ID: 4004765
[TBL] [Abstract][Full Text] [Related]
16. Intrathecal administration of 4-hydroperoxycyclophosphamide in rhesus monkeys.
Arndt CA; Colvin OM; Balis FM; Lester CM; Johnson G; Poplack DG
Cancer Res; 1987 Nov; 47(22):5932-4. PubMed ID: 3664493
[TBL] [Abstract][Full Text] [Related]
17. Reduction in immunogenicity and clearance rate of Escherichia coli L-asparaginase by modification with monomethoxypolyethylene glycol.
Kamisaki Y; Wada H; Yagura T; Matsushima A; Inada Y
J Pharmacol Exp Ther; 1981 Feb; 216(2):410-4. PubMed ID: 7007618
[TBL] [Abstract][Full Text] [Related]
18. Infusion of red blood cell-loaded asparaginase in monkey. Immunologic, metabolic, and toxicologic consequences.
Updike SJ; Wakamiya RT
J Lab Clin Med; 1983 May; 101(5):679-91. PubMed ID: 6187874
[TBL] [Abstract][Full Text] [Related]
19. Phase I evaluation of succinylated Acinetobacter glutaminase-asparaginase in adults.
Warrell RP; Chou TC; Gordon C; Tan C; Roberts J; Sternberg SS; Philips FS; Young CW
Cancer Res; 1980 Dec; 40(12):4546-51. PubMed ID: 7438089
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase.
Panetta JC; Liu Y; Bottiglieri T; Arning E; Cheng C; Karol SE; Yang JJ; Zhou Y; Inaba H; Pui CH; Jeha S; Relling MV
Cancer Chemother Pharmacol; 2021 Oct; 88(4):655-664. PubMed ID: 34170389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]